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Stem cells versus chondrocytes for cartilage repair
A. Caplan, United States of America 
The current standard of clinical care for cartilage repair is 
microfracture especially for small, focal defects in the articular 
cartilage of the knee. The actual sequence of events and outcome 
of this procedure are understudied, considering the pervasive use of 
this technique. It is assumed that the microfracture produces a bleed 
and subsequent clot. It is imagined that Mesenchymal Stem Cells 
(MSCs) come up from the bottom (i.e., marrow) and contribute to 
UIFSFTVMUJOHUJTTVFUIBUSFQMBDFTUIFDMPU5IJTSFQBJSUJTTVFJT¾SNPO
BSUISPTDPQJDQSPCJOHBOEJTUIPVHIUUPCF¾CSPVTPS¾CSPDBSUJMBHF
(at best). In general, if successful, this procedure decreases pain, 
provides a smooth surface and lasts for several months to years. The 
FYQFDUBUJPO JTUIBUVMUJNBUFMZUIJT¾CSPVTUJTTVFXJMM GBJMBOEPUIFS
operative approaches will be required. In a sense, microfracture may 
be a form of in vivo stem cell therapy. I would expect this to be highly 
successful in patients below the age of 10 and not successful above 
the age of 65. 
The current use of tissue-engineered implants involves autologous 
chondrocytes in a defect either placed within a scaffold, or below 
BQFSJPTUFVN¿BQ5IF MPOHUFSNTVDDFTTPG UIFTFQSPDFEVSFTBSF
comparable to microfracture and some data suggest that these may 
CF CFUUFS CFDBVTF UIF EFGFDUT BSF ¾MMFE XJUINPSF DBSUJMBHF UIBO
¾CSPVTUJTTVF
Several groups have provided data from preclinical models using 
chondrocytes (both allo- and autologous) and MSCs (both allo- 
and autologous) in cartilage repair/regeneration procedures. In all 
cases, the cells have been culture-expanded and combined with 
scaffolds of natural and/or man-made polymers. The expanded cells 
are clearly different from their in vivo counterparts and the issue is 
whether the redifferentiation or initial differentiation of these cells 
will produce the appropriate repair cartilage upon implantation. 
The lecture will review research from the Skeletal Research Center and 
other labs on the comparisons between chondrocytes from various 
anatomic locations and MSCs. The challenge for the investigators 
who work with MSCs is to understand what sequential exposure 
pattern of bioactive factors is required to fabricate cartilage tissue 
that has the proper macromolecular composition and mechanical 
properties to be implanted into either chondral or osteochondral 
defects. Unresolved issues are how to control the differentiation and 
biosynthetic sequence to fabricate cartilage that is anatomical site 
TQFDJ¾D*OBEEJUJPOUIFTUSBUJ¾DBUJPOPGNPMFDVMBSDPNQPVOETGSPN
top to the bony bottom of cartilage will require additional control 
elements. Although the future expectations are very positive for 
these approaches, the challenges are currently quite high. Supported 
by grants from National Institutes of Health. 
27.3
Clinical use of stem cells in cartilage repair. 
L. Fortier, United States of America 
The purpose of this presentation is to review the types of stem cells 
in clinical application for cartilage repair, and the functional outcome 
associated with their use. 
Manuscripts and clinical trials detailing the clinical implantation of 
stem cells for cartilage repair were reviewed. 
There are very few reports of the clinical application of mesenchymal 
stem cells (MSC), and only animal studies of embryonic stem cells 
(ES) for cartilage regeneration despite the numerous manuscripts 
investigating mechanisms to enhance chondrogenic differentiation 
of ES or MSCs. Tissue engineering studies indicate that in order to 
restore the cartilage matrix and thereby the mechanical integrity of 
an articular cartilage defect, a cell source is needed to synthesize the 
extracellular matrix. However, the optimal cell type remains to be 
JEFOUJ¾FEBTFJUIFSNBUVSFDIPOESPDZUFTPSTUFNDFMMTBOEJGTUFN
cells, the preferred tissue source would then need to be determined. 
It is also unclear if pluripotent stem cells, implanted in an articular 
cartilage or cartilage/bone defect, will spontaneously differentiate 
into chondrocytes, or if it is necessary to drive stem cells down a 
chondrogenic pathway prior to implantation. Another unresolved 
issue is the clinical importance of type X collagen synthesis by MSCs 
undergoing chondrogenesis in vitro. The concern is that these cells 
could continue onto hypertrophy and apoptosis. 
Embryonic stem cells have not been used in clinical patients, and 
although studies in rodents are encouraging, is appears as through 
optimization of implantation protocols is important to avoid teratoma 
formation.1,2 
Adult-derived stem cells from bone marrow, muscle, synovium, 
GBUQFSJPTUFVNBOE UIFTVQFS¾DJBM [POFPGNBUVSFDBSUJMBHFIBWF
been investigated in vitro for cartilage regeneration applications, 
but only bone marrow-derived MSCs have been used clinically. 
Although not an explicit MSC therapy, microfracture is thought 
to allow the ingress of MSCs from the underlying bone marrow. A 
distinct advantage of microfracture is its immediate availability for 
point-of-care application. Cartilage repair and restoration of joint 
function following microfracture has been investigated in horses3,4, 
humans5, and non-human primates6. Combined, these studies 
suggest that microfracture results in increased tissue volume and 
improved patient comfort and function compared to no treatment. 
)PXFWFSSFQBJSUJTTVFGPSNFEBGUFSNJDSPGSBDUVSFSFNBJOTEF¾DJFOU
in key extracellular matrix components such as aggrecan and 
DPMMBHFOUZQF**5IFSFQBJSUJTTVFGPSNFEJTEF¾DJFOUJODSJUJDBMNBUSJY
proteins and in many instances deteriorates, resulting in the return 
of clinical signs, within two years of the microfracture procedure. 
Another point-of-care MSC-based therapy is marketed under the 
trade name of Chondrogen (Osiris Therapeutic Inc.) and is in phase 
I/II clinical trials. Chondrogen is autologous MSCs injected into the 
joint capsule, and is primarily aimed at meniscus regeneration. An 
interim report released in February 2007, stated that Chondrogen 
did not increase meniscus volume, but in about 30% of patients 
“improvement in baseline cartilage and joint condition was noted in 
patients treated with the stem cell drug”. 
To increase the number of autogenous MSCs implanted in a cartilage 
defect as compared to microfracture, a study was performed where 
autogenous MSCs were propagated in tissue culture, and implanted 
JOBVUPHFOPVT¾CSJOJOUPGVMMUIJDLOFTTDBSUJMBHFEFGFDUT5IF.4$
¾CSJODPOTUSVDUT MFBE UPFOIBODFEFBSMZDIPOESPHFOFTJTCVU UIFZ
EJEOPU TJHOJ¾DBOUMZ FOIBODF UIF MPOHUFSNIJTUPMPHJD BQQFBSBODF
or biochemical composition of full-thickness cartilage lesions.7 Our 
laboratory is presently working towards development of a patient-side 
method to concentrate stem cells in bone marrow using a specialized 
centrifugation technique. In addition to being a table-side technique, 
other advantages of such a bone marrow aspirate concentrate 
(BMAC) include the simultaneous concentration of platelets which 
serve as a reservoir for numerous chondrogenic growth factors, and 
the BMAC slurry can be implanted under arthroscopic guidance. This 
BMAC graft construct has been arthroscopically implanted into full-
thickness cartilage defects in the equine lateral trochlear ridge and 
the 3T MRI images and tissues are presently being evaluated. 
Studies investigating the chondrogenic potential of stem cells 
suggest that synthesis of a neocartilage matrix is possible using 
stem cells from a variety of tissue sources. Present clinical data 
suggests that MSCs do not fully repair articular cartilage defects. 
However, there are numerous variables including other types of 
